Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Hanjin | - |
dc.contributor.author | Yu, Hee Tae | - |
dc.contributor.author | Kim, Tae-Hoon | - |
dc.contributor.author | Park, Junbeom | - |
dc.contributor.author | Park, Jin-Kyu | - |
dc.contributor.author | Kang, Ki-Woon | - |
dc.contributor.author | Shim, Jaemin | - |
dc.contributor.author | Kim, Jin-Bae | - |
dc.contributor.author | Kim, Jun | - |
dc.contributor.author | Choi, Eue-Keun | - |
dc.contributor.author | Park, Hyung Wook | - |
dc.contributor.author | Lee, Young Soo | - |
dc.contributor.author | Joung, Boyoung | - |
dc.date.accessioned | 2023-05-03T11:08:20Z | - |
dc.date.available | 2023-05-03T11:08:20Z | - |
dc.date.created | 2023-01-05 | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/185152 | - |
dc.description.abstract | Purpose: Advanced chronic kidney disease (CKD), including end-stage renal disease (ESRD) on dialysis, increases thromboembolic risk among patients with atrial fibrillation (AF). This study examined the comparative safety and efficacy of direct-acting oral anticoagulant (DOAC) compared to warfarin or no oral anticoagulant (OAC) in AF patients with advanced CKD or ESRD on dialysis. Materials and Methods: Using data from the COmparison study of Drugs for symptom control and complication prEvention of AF (CODE-AF) registry, 260 non-valvular AF patients with advanced CKD (defined as estimated glomerular filtration rate <30 mL/min per 1.73/m(2)) or ESRD on dialysis were enrolled from June 2016 to July 2020. The study population was categorized into DOAC, warfarin, and no OAC groups; and differences in major or clinically relevant non-major (CRNM) bleeding, stroke/systemic embolism (SE), myocardial infarction/critical limb ischemia (CLI), and death were assessed. Results: During a median 24 months of follow-up, major or CRNM bleeding risk was significantly reduced in the DOAC group compared to the warfarin group [hazard ratio (HR) 0.11, 95% confidence interval (CI) 0.01 to 0.93, p=0.043]. In addition, the risk of composite adverse clinical outcomes (major or CRNM bleeding, stroke/SE, myocardial infarction/CLI, and death) was significantly reduced in the DOAC group compared to the no OAC group (HR 0.16, 95% CI 0.03 to 0.91, p=0.039). Conclusion: Among AF patients with advanced CKD or ESRD on dialysis, DOAC was associated with a lower risk of major or CRNM bleeding compared to warfarin and a lower risk of composite adverse clinical outcomes compared to no OAC. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | YONSEI UNIV COLL MEDICINE | - |
dc.title | Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Jin-Kyu | - |
dc.identifier.doi | 10.3349/ymj.2022.0455 | - |
dc.identifier.scopusid | 2-s2.0-85144641346 | - |
dc.identifier.wosid | 000919661600003 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, v.64, no.1, pp.18 - 24 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.citation.title | YONSEI MEDICAL JOURNAL | - |
dc.citation.volume | 64 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 18 | - |
dc.citation.endPage | 24 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002906904 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | ANTITHROMBOTIC THERAPY | - |
dc.subject.keywordPlus | WARFARIN | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | RIVAROXABAN | - |
dc.subject.keywordPlus | APIXABAN | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | STROKE | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | DABIGATRAN | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordAuthor | Anticoagulant | - |
dc.subject.keywordAuthor | atrial fibrillation | - |
dc.subject.keywordAuthor | bleeding | - |
dc.subject.keywordAuthor | dialysis | - |
dc.subject.keywordAuthor | stroke | - |
dc.identifier.url | https://eymj.org/DOIx.php?id=10.3349/ymj.2022.0455 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.